Article 223-16 of the General Regulation of the French Financial Markets Authority
(AMF – Autorité des Marchés Financiers)
Press release
Avignon, February 10, 2011
31.01.2011
Total number of outstanding shares forming the capital
|
6,410,931 |
| Total number of outstanding shares forming the capital with voting rights
|
4,959,935 |
| Number of shares with double voting rights | 86,947 |
| Total number of gross voting rights | 5,046,882 |
Number of shares without voting rights
|
- 9,697 |
| Total number of exercisable voting rights* | 5,037,185 |
*Real number of voting rights = total number of voting rights – number of shares without voting rights
If you would like to receive FINANCIAL information about Naturex by e-mail, go to: www.naturex.com
Naturex est coté depuis octobre 1996 sur NYSE Euronext à Paris, compartiment B
Number of shares in the capital: 6,410,931
MNEMO: NRX - Reuters: NATU.PA - Bloomberg: NRX:FP |
About Naturex
Naturex is the global leader in speciality plant-based natural ingredients.
The Group, organised around three strategic markets - Food & Beverage, Nutrition & Health and Personal Care - produces and markets specialty plant-based natural ingredients for the food, nutraceutical, pharmaceutical and cosmetic industries.
Naturex's head office is based in Avignon. The company employs more than 950 people and has high-performance industrial resources through its 11 industrial sites in Europe (France, Italy, Spain, the United Kingdom and Switzerland), as well as in Morocco, the United States, Brazil and Australia. It also benefits from sales presence around the world through a dedicated network in 16 countries (France, Italy, Spain, the United Kingdom, Belgium, Germany, Switzerland, Russia, U.A.E., Thailand, Singapore, Japan, China, Australia, the United States and Brazil).
Naturex's sound performance is linked to the fast-growing demand for natural products and its capacity to provide manufacturers with the personalised means to meet the requirements of their end consumers. The Group's strength lies in its ability to position itself on specific products which constitute niche markets, thanks to sustained Research & Development.
| > Naturex Contacts | |
| Jacques Dikansky Chairman and CEO Tel.: +33 (0)4 90 23 96 89 naturex@naturex.com |
Thierry Lambert Vice-Chairman and CFO Tel.: +33 (0)4 90 23 96 89 t.lambert@naturex.com |
| Carole Alexandre Investor Relations Tel.: +33 (0)4 90 23 78 28 c.alexandre@naturex.com |
|
> Actus Finance Contacts |
|
| Anne Catherine Bonjour Actus Press Relations Tel.: +33 (0)1 53 67 36 93 acbonjour@actus.fr |
Jérôme Fabreguettes-Leib Investor Relations Tel.: +33 (0)1 77 35 04 36 jfl@actus.fr |
